Corpus ID: 9091384

UK-315716/UK-240455. Pfizer.

@article{Capelli2001UK315716UK240455P,
  title={UK-315716/UK-240455. Pfizer.},
  author={A. Capelli and F. Micheli},
  journal={Current opinion in investigational drugs},
  year={2001},
  volume={2 12},
  pages={
          1737-9
        }
}
Pfizer is developing the atropoisomeric quinoxalinediones, UK-315716 and UK-240255, from a series of NMDA/glycine antagonists for the potential treatment of stroke. Both are compounds are undergoing clinical trials. UK-315716 has improved aqueous solubility and in vivo efficacy over UK-240455, and a lower projected clinical dose of 200 mg compared to 500 mg with UK-240455. 
1 Citations
Assessing atropisomer axial chirality in drug discovery and development.
  • 199